Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7385940 | 1.00 | PAM (0.58) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL97891 | 1.00 | PAM (0.58) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL7377485 | 0.83 | MAOB (0.64) | PAMIDO1MAOBALDH1A1LMNA | |
| SCHEMBL9777486 | 0.80 | IDO1 (0.58) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL4863423 | 0.80 | IDO1 (0.58) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL94815 | 0.80 | PAM (0.54) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL94816 | 0.80 | PAM (0.54) | PAMIDO1MAOBHTR2AALDH1A1 | |
| SCHEMBL2308340 | 0.79 | IDO1 (0.58) | PAMIDO1MAOBHTR2A | |
| SCHEMBL1172825 | 0.79 | IDO1 (0.58) | PAMIDO1MAOBHTR2A | |
| SCHEMBL2399949 | 0.78 | PAM (0.52) | PAMIDO1MAOBHTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440591-B | Synthesis method of chiral dihydrosilane compound | 浙江大学 | 2021-03-05 | — | — | CN | claimed |
| US-10053539-B2 | Composition for film formation, film, production method of patterned substrate, and compound | JSR CORPORATION (JP) | 2018-08-21 | — | — | US | claimed |
| EP-1423372-B1 | TRIAZINE COMPOUNDS, POLYMERS COMPRISING TRIAZINE STRUCTURAL UNITS, AND PROCESSES FOR THE PREPARATION OF THESE POLYMERS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2016-07-20 | — | — | EP | claimed |
| EP-1915130-B1 | LIQUID FORMULATIONS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | claimed |
| US-20140242119-A1 | AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | claimed |
| US-20130210924-A1 | Dosage Regimen of Diaryl Sulfide Derivatives | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | claimed |
| US-20130172297-A1 | Treatment of Autoimmune Diseases | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | claimed |
| EP-1944026-B1 | Use of EDG receptor binding agents in cancer | NOVARTIS AG (CH) | 2013-06-26 | — | — | EP | claimed |
| EP-2566473-A1 | DOSAGE REGIMEN OF DIARYL SULFIDE DERIVATIVES | Novartis AG (CH) | 2013-03-13 | — | — | EP | claimed |
| EP-2566470-A1 | TREATMENT OF AUTOIMMUNE DISEASES | Novartis AG (CH) | 2013-03-13 | — | — | EP | claimed |
| EP-0298955-A1 | UTILIZATION OF $g(a)-CETOCARBONIC ACID HYDRAZONES AND OXINES FOR TREATING CARDIAC OR CIRCULATORY DISEASES | Roche Diagnostics GmbH (DE) | 1989-01-18 | — | — | EP | claimed |
| WO-1986000522-A1 | UTILIZATION OF alpha-CETOCARBONIC ACID HYDRAZONES AND OXINES FOR TREATING CARDIAC OR CIRCULATORY DISEASES | BOEHRINGER MANNHEIM GMBH (DE) | 1986-01-30 | — | — | WO | claimed |
| EP-0048911-B1 | O-SUBSTITUTED OXIMES OF ALPHA-KETOCARBOXYLIC ACID, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Roche Diagnostics GmbH (DE) | 1984-12-05 | — | — | EP | claimed |
| US-4425360-A | Pharmacologically active novel O-substituted pyruvic acid oximes | BOEHRINGER MANNHEIM GMBH (DE) | 1984-01-10 | — | — | US | claimed |
| EP-0005610-B1 | 1-(HETEROCYCLYLALKYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONES, THEIR PREPARATION, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS BETA-ADRENERGIC RECEPTOR BLOCKERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-12-15 | — | — | EP | claimed |
| EP-0048911-A2 | O-substituted oximes of alpha-ketocarboxylic acid, preparation and pharmaceutical compositions | Roche Diagnostics GmbH (DE) | 1982-04-07 | — | — | EP | claimed |
| US-4262013-A | ANTILIPEMIC AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-04-14 | — | — | US | claimed |
| US-4198425-A | ANTILIPEMIC AGENTS | SANKYO COMPANY LIMITED (JP) | 1980-04-15 | — | — | US | claimed |
| US-4181802-A | ADRENERGIC BLOCKING AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-01-01 | — | — | US | claimed |
| EP-0005610-A2 | 1-(Heterocyclylalkyl)-1,3-dihydro-2H-benzimidazol-2-ones, their preparation, their pharmaceutical compositions and their use as beta-adrenergic receptor blockers | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172297-A1 | Treatment of Autoimmune Diseases | SSB, C3AR1, HRH3 | PAM 1706/4885IDO1 984/4885MAOB 904/4885 |
| US-20130210924-A1 | Dosage Regimen of Diaryl Sulfide Derivatives | SULT2A1, CCNY, SULT1A1 | PAM 1580/4885IDO1 2867/4885MAOB 924/4885 |
| US-20140242119-A1 | AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES | PMP22, AQP4, ADH1A | PAM 565/4885IDO1 1293/4885MAOB 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.